EMA401, nouveau mode d’action dans le traitement des douleurs neuropathiques périphériques : Études EMPHENE et EMPADINE
Sign Up to like & getrecommendations! Published in 2019 at "Revue Neurologique"
DOI: 10.1016/j.neurol.2019.01.386
Abstract: Introduction Les douleurs neuropathiques peripheriques, affectant pres de 10 % de la population, representent un besoin medical non satisfait. EMA401 (Olodanrigan) est le premier antagoniste du recepteur de l’angiotensine II type 2. Objectifs Les objectifs principaux… read more here.
Keywords: ema401 nouveau; douleurs neuropathiques; emphene empadine; douleur ... See more keywords
Nonopioid analgesics discovery and the Valley of Death: EMA401 from concept to clinical trial.
Sign Up to like & getrecommendations! Published in 2022 at "Pain"
DOI: 10.1097/j.pain.0000000000002675
Abstract: ABSTRACT Translation of promising preclinical efficacy data for investigational analgesics to positive clinical trial outcomes is limited, despite the large collective effort to date. However, one target with positive proof-of-concept clinical trial data is the… read more here.
Keywords: at2 receptor; concept clinical; ema401; trial ... See more keywords